1 Efficacy and longevity of immune response to 3rd COVID-19 vaccine and effectiveness of

a 4th dose in severely immunocompromised patients with cancer

- 4 Astha Thakkar¹, Kith Pradhan², Benjamin Duva¹, Juan Manuel Carreño^{3,5}, Srabani Sahu¹, Victor
- 5 Thiruthuvanathan¹, Sean Campbell⁶, Sonia Gallego¹, Tushar D Bhagat¹, Johanna Rivera⁷,
- 6 Gaurav Choudhary¹, Raul Olea¹, Maite Sabalza⁸, Lauren C. Shapiro¹, Matthew Lee¹, Ryann
- Quinn¹, Ioannis Mantzaris¹, Edward Chu¹,, Britta Will¹, Liise-anne Pirofski⁷, Florian Krammer^{3,4,5,}
- 8 Amit Verma^{1*}, Balazs Halmos^{1*}
- Department of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of
 Medicine
 - 2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine
 - 3. Department of Microbiology, Icahn School of Medicine at Mount Sinai
- Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine
 at Mount Sinai
 - 5. Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai
 - 6. Department of Pathology, Montefiore Medical Center
 - 7. Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center
 - 8. EUROIMMUN, US
- 22 * Correspondence to:
- 24 Dr. Balazs Halmos, bahalmos@montefiore.org
- 25 **or**

2

3

11

12

15

16

17

18

19

20

21

23

27

29

30

- 26 Dr. Amit Verma, amit.verma@einsteinmed.edu
- 28 Keywords: COVID-19, Vaccine, Booster, Cancer
- 32 **Abstract** (150 words)
- 33 Cancer patients show increased morbidity with COVID-19 and need effective immunization
- 34 strategies. We demonstrate that a 3rd dose of COVID-19 vaccine leads to seroconversion in
- 35 57% of patients that were seronegative after primary vaccination. The immune response is
- durable as assessed by anti-S antibody titers, T-cell activity and neutralization activity against
- 37 wild-type SARS-CoV2 and BA1.1.529 at 6 months of follow up. A subset of severely
- immunocompromised hematologic malignancy patients were unable to mount adequate immune

response after the 3rd dose and were treated with a 4th dose in a prospective clinical trial which led to adequate immune-boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant. These results indicate that vaccine booster-induced immunity is durable in cancer patients and additional doses can further stimulate immunity in a subset of hematologic malignancy patients.

Statement of significance

We demonstrate that a 3rd dose of vaccine leads to seroconversion in 57% of negative patients with durable immune responses at 6 months. A 4th dose of vaccine can seroconvert hematologic malignancy patients with higher baseline IgM and CD19 levels.

Introduction

It is now well-established that coronavirus disease 2019 (COVID-19) in patients with cancer carries a higher morbidity and mortality, especially in patients with hematologic malignancies[1-5]. While overall case fatality has decreased over time, mostly related to the impact of broad vaccinations and improved supportive/antimicrobial management, a higher case fatality rate was noted amongst cancer patients even during the Omicron (B.1.1.529) wave [6-8]. Advanced age, co-morbidities and performance status have emerged as key factors adversely impacting outcomes amongst patients with a cancer diagnosis[9]. Effective vaccines have been developed and authorized by the FDA to combat this pandemic[10, 11]. However, emerging data suggests that despite these vaccines inducing high levels of immunity in the general population, patients with hematologic malignancies have lower rates of seroconversion as defined by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibody (anti-S antibody) titers [12, 13]. Evidence has also suggested that specific therapies, such as anti-CD20 antibodies, BTK-inhibitors and stem cell transplantation (SCT) have an association with lower rates of seroconversion [14-16].

We previously published preliminary results of a study defining notable impacts of a 3rd booster dose of vaccine, demonstrating a more than 50% seroconversion rate amongst patients remaining seronegative after primary vaccinations[17]. Since then, we have completed our entire primary cohort to assess initial responses with a broad array of immunological assays along with now additional significant follow up allowing assessment of key aspects of waning immunity. Importantly, we additionally conducted a trial assessing the efficacy of fourth dose vaccinations amongst a highly immune suppressed group of patients with no or limited response to a prior booster vaccine dose. Here we present results of both key cohorts including results of serological, T cell and neutralization assays as well as correlations with other baseline clinical, treatment and laboratory parameters.

Methods

Patient recruitment and follow-up (ClinicalTrials.gov identifier NCT05016622):

3rd dose study

81

93

94

95

96

97

98

99

100

101

102

103104

105

106

107

108 109

- We recruited patients via an informed consent process. Patients were required to be >18 years 82 of age and have a cancer diagnosis either on active treatment or requiring active surveillance. 83 84 Patients were also required to have received 2 doses of the mRNA COVID-19 vaccine or 1 dose of the adenoviral vaccine prior to enrollment. After drawing baseline labs that included spike 85 antibody, a sample for T-cell assay and a biobank sample, patients received booster mRNA 86 vaccine (initially BNT162b2 per protocol, which was later amended to allow for booster mRNA-87 1273 vaccine after the Food and Drug Administration (FDA) authorized "booster" doses in fall of 88 2021). Patients who had received Ad26.CoV2.S vaccine received a booster BNT162b2 vaccine. 89 90 The patients then returned for follow-up 4 weeks and 4-6 months after their booster dose and their labs were repeated (Supplementary Fig 1). 91
- 92 4th dose study
 - We have previously reported preliminary findings of a 56% seroconversion rate for patients with cancer who did not have a detectable immune response after 2 doses[17]. For patients who did not seroconvert after 3 doses or had low antibody response (<1000 AU/mL as determined by our in-house assay, Abbott) we hypothesized whether a 'mix and match' strategy with 4th dose of COVID-19 vaccine would induce seroconversion/improved boosting of the humoral antibody responses. To study this, we designed a protocol wherein patients who had received 3 prior doses of mRNA vaccines and had undetectable anti-S antibody or had an anti-S antibody level of <1000 AU/mL measured at least 14 days after 3rd dose, would be randomized to an mRNA vs adenoviral 4th vaccine dose. Responses would be then assessed at 4 weeks after the 4th dose through measurement of anti-S antibody results. We also measured complete blood counts, quantitative immunoglobulin levels (IgG, IgA and IgM), lymphocyte subsets, T-cell responses and neutralization activity at baseline and 4 weeks for each of these patients. Following the implementation of this protocol, the Centers for Disease Control (CDC) published a statement that advised that the mRNA vaccines should be preferentially administered over the adenoviral vaccines given concern over rare side effects such as thrombocytopenia and thrombosis syndrome. Following this advisory, we amended our protocol to allow recruitment in a cohort that would receive a 4th dose of the BNT162b2 vaccine to comply with CDC guidelines (Supplementary Fig 1).
- 111 Anti-SARS-CoV2 Spike (anti-S) antibody assay
- The AdviseDx SARS-CoV-2 IgG II assay was used for the assessment of anti-S IgG antibody. 112 113 AdviseDx is an automated, two-step chemiluminescent immunoassay performed on the Abbott i1000SR instrument. The assay is designed to detect IgG antibodies directed against the 114 receptor binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. The RBD 115 116 is a portion of the S1 subunit of the viral spike protein and has high affinity for the angiotensin converting enzyme 2 (ACE2) receptor on the cellular membrane[18, 19] The procedure, in brief, 117 118 is as follows. Patient serum containing IgG antibodies directed against the RBD is bound to microparticles coated with SARS-CoV-2 antigen. The mixture is then washed of unbound IgG 119 and anti-human IgG, acridinium-labeled, secondary antibody is added and incubated. Following 120 another wash, sodium hydroxide is added and the acridinium undergoes an oxidative reaction, 121 which releases light energy which is detected by the instrument and expressed as relative light 122 units (RLU). There is a direct relationship between the amount of anti-spike IgG antibody and 123 124 the RLU detected by the system optics. The RLU values are fit to a logistic curve which was used to calibrate the instrument and expresses results as a concentration in AU/mL (arbitrary 125

units/milliliter). This assay recently has shown high sensitivity (100%) and positive percent agreement with other platforms including a surrogate neutralization assay)[20] and also demonstrated high specificity both in the post SARS-CoV-2 infection and post vaccination settings. The cutoff value for this assay is 50 AU/mL with <50 AU/ml values reported as negative and the maximum value is 50000 AU/mL.

SARS-CoV-2 Interferon Gamma Release Assay

126

127

128 129

130

131132133

134

135

136

137

138

139

140 141

142

143

144145

146147

148

149

150 151

152

153154

155

156

157

158

159

160

161

162

163

164 165

166

167

168

169 170

EUROIMMUN SARS-COV-2 Interferon Gamma Release Assav (Quan-T-Cell SARS-CoV-2) was used for the assessment of patients' T-cell response to SARS-CoV-2 antigens through analysis of the production of interferon gamma by patient T-cells after exposure to SARS- CoV-2 specific proteins. The assay does not differentiate between vaccineor infection-induced T-cell responses. The SARS-CoV-2 IGRA assay is performed in two steps as per manufacturer instructions, and a brief protocol follows. First, patient samples from lithium heparin vacutainers are aliquoted into three separate tubes each. These tubes contain either nothing ('blank'), general T-cell activating proteins ('mitogen'), or components of the S1 domain of SARS-CoV-2 ('SARS-CoV-2 activated'). These samples were incubated at 37 degrees for 24 hours before being centrifuged and the plasma separated and frozen at -80 degrees for later analysis. Samples were then batched to be run as a full 96 well plate along with calibrators and controls. Plasma samples were unfrozen and added to an ELISA plate, which was prepared with monoclonal interferon-gamma binding antibodies, along with calibrators and controls. After incubation at room temperature the plate was washed and biotin-labeled anti-interferon gamma antibody was added to bind the patient interferon gamma bound to the plate. The plate was again incubated before being washed of excess antibody and a streptavidin-bound horseradish peroxidase (HRP) enzyme added, which binds strongly to the biotin-labeled antibodies present. This was again incubated and then washed of excess enzyme before a solution of H₂O₂ and TMB (3,3', 5,5;-tetramethylbenzidine, a peroxide-reactive chromogen) is added and allowed to react in the dark for 20 minutes. The reaction is then stopped through the addition of sulfuric acid and the results read at 450 nM with background subtraction at 650 nM. Results for controls and samples were quantified by the calibration curve generated on the same plate, and results were interpreted as long as controls were within the pre-specified range. Blank results for each specimen set were subtracted from each tube in the set and the mIU/mL for both the mitogen and SARS-CoV-2 activated samples were determined with the calibration curve. Samples with mitogen results below 400 mIU/mL were considered 'invalid', as the overall T-cell activity for that set was too low, and excluded from analysis. All other sample sets were interpreted as per manufacturer's instructions based on the SARS-CoV-2 activated sample results: less than 100 mIU/mL were denoted as negative, and greater than or equal to 100 mIU/mL were denoted as positive.

Neutralization assays

Surrogate Virus Neutralization assay for wild type SARS-CoV-2

The SARS-CoV-2 Surrogate Virus Neutralization Test Kit was used to measure antibodies that inhibit the interaction between viral RBD and ACE2 receptor. This test kit uses purified human ACE2 (hACE2) protein-coated enzyme-linked immunosorbent assay (ELISA) plates and horseradish peroxidase (HRP)-conjugated RBD to monitor the presence of circulating

antibodies in samples, including peripheral/capillary blood, serum, and plasma, which block the interaction of RBD-HRP with ACE2 with excellent correlation with the gold standard live virus plague reduction neutralization test.

The kit contains two key components: RBD-HRP and hACE2. The protein-protein interaction between RBD-HRP and hACE2 is disrupted by neutralizing antibodies against SARS-CoV-2 RBD, if present in a sample. After mixing the sample dilutions with the RBD-HRP solution, components are allowed to bind to the RBD. The neutralization antibody complexed to RBD-HRP remains in the supernatant and is removed during washing, The yellow color of the hACE2-coated wells is determined by the RBD HRP binding to the hACE2-coated wells after incubation with 3,3',5,5'-tetramethylbenzidine (TMB), followed by a stop solution. After the addition of the stop solution, a light-yellow color results from blocking agents interacting with RBDs and inhibiting hACE2 interactions.

Microneutralization assay (MNT).

171

172

173

174

175

176 177

178179

180

181

182183

184

185

186

187

188 189

190

191 192

193

194 195

196

197

198

199 200

201

202203

204

205

206 207

208 209

210

211

212

213

MNT assays were performed in a biosafety level 3 facility at the Icahn School of Medicine at Mount Sinai (ISMMS) as previously described[21]. Briefly, Vero E6-TMPRSS2 cells were seeded in 96-well cell culture plates at 20,000/well in complete Dulbecco's Modified Eagle Medium (cDMEM). The following day, heat-inactivated serum samples were serially diluted (3fold) starting at a 1:10 dilution in 1x MEM (10x minimal essential medium (Gibco), 2□mM Lglutamine. 0.1% sodium bicarbonate (Gibco), 10 □mM 4-(2-hvdroxvethyl)-1piperazineethanesulfonic acid (HEPES; Gibco), 100 U ml-1 penicillin, 100 ug/ml-1 streptomycin (Gibco) and 0.2% bovine serum albumin (MP Biomedicals)) supplemented with 10% fetal bovine serum (FBS). The virus diluted at 10,000 tissue culture infectious dose 50% (TCID₅₀) per ml of 1x MEM was added to the serum dilutions and incubated for 1 □h at room temperature (RT). After removal of cDMEM from Vero E6 cells, 120 □µl/well of the virus - serum mix were added to the cells and plates were incubated at 37 □ °C for 1 □ h. Mix was removed and 100 □ µl/well of each corresponding serum dilutions were added in a mirror fashion to the cell plates. Additional 100 □ µl/well of 1× MEM 1% FBS (Corning) were added to the cells. Plates were incubated for 48 □ h at 37 □ °C and fixed with a 10% paraformaldehyde solution (PFA, Polysciences) for 24 □ h at 4 □ °C.

For staining, plates were washed with $200 \square \mu I$ of PBS. Cells were permeabilized with $150 \square \mu I/\text{well}$ PBS containing 0.1% Triton X-100 for $15 \square \text{min}$ at RT. Plates were washed 3x with PBST and blocked with 3% milk (American Bio) in PBST for $1 \square h$ at RT. Blocking solution was removed and $100 \square \mu I/\text{well}$ of the biotinylated mAb 1C7C7 anti-SARS nucleoprotein antibody (generated at the Center for Therapeutic Antibody Development at the ISMMS) were added at $2 \mu g/\text{mI}$ for $1 \square h$ at RT. Plates were then washed 3x with PBST and the secondary antibody goat anti-mouse IgG-HRP (Rockland Immunochemicals) was added at 1:3,000 in blocking solution for $1 \square h$ at RT. Plates were washed 3x with PBST, and SIGMAFAST OPD (o-phenylenediamine, Sigma-Aldrich) was added for $10 \min$ at RT. The reaction was stopped with $50 \square \mu I/\text{well}$ $3 \square M$ hydrochloric acid to the mixture. Optical density $(0D_{490})$ was measured on an automated plater reader (Sinergy 4, BioTek). The inhibitory dilution 50% were calculated as previously described [22].

Statistical analysis

216

217

218 219

220

221

222

223

224

225

226

227

228

229 230

231

232

233

The primary endpoint of the third dose study was to assess the rate of booster induced seroconversion amongst patients who remained seronegative at least 28 days following standard set of FDA authorized COVID-19 vaccinations. We hypothesized that booster dosing would convert at least 30% of the enrolled seronegative patients to seropositive as defined by our institutional Clinical Laboratory Improvement Amendments (CLIA) certified SARS-CoV-2 spike IgG assay (as compared to 10% as our null hypothesis). In a pre-specified analysis, at least 26 evaluable seronegative patients were required to have sufficient power to be able to reach this assessment. A McNemar's test was used to determine the equality of marginal frequencies for paired nominal data with the aid of a homogeneity of stratum effects (HSE) test to check if the effect was the same across all levels of a stratifying variable [23]. A Wilcox test was used to determine if titers of two paired observations have changed over time subsequently using a Kruskal Wallis test to determine if this difference is associated with another variable. For the 4th dose study, a responder was considered any patient who showed seroconversion from negative anti-S antibody to positive anti-S antibody at 4 weeks after 4th dose or increase in titer to >1000 AU/mL at 4 weeks after the 4th dose. An alpha < 0.05 was considered statistically significant. Correlation between continuous variables was assessed using Spearman's test. All analyses were performed in R (version 3.6.2). This study was approved by The Albert Einstein College of Medicine Institutional Board Review.

Results

Duration of immune responsiveness after third dose of covid vaccine in cancer patients:

Baseline characteristics

We previously reported outcomes for 88 patients enrolled into this study[17]. Here we present our final results for the complete cohort of 106 patients that were enrolled into this study for assessment of the primary endpoint of response at 4 weeks as well as 47 patients who completed 4-6 month follow-up. The baseline characteristics of this cohort are summarized in **Table 1**. The median age was 68 years (63.25-76.5 years)). Fifty five percent (58/106) of patients were female and 45% (48/106) were male. Our cohort was ethnically diverse and included 34% (36/106) Caucasian, 31% (33/106) African-American, 25% (27/106) Hispanic and 8% (9/106) Asian patients. Majority of patients had received mRNA vaccines at baseline. Sixty-eight percent (72/106) received BNT162b2, 26% (28/106) received mRNA-1273 and 6% (6/106) had received Ad26.CoV2.S. Seventy four percent of patients (78/106) received a booster BNT162b2 vaccine and 26% (28/106) patients received booster mRNA-1273 vaccine. The majority of the patients, 62% (66/106), had a hematologic malignancy and 38% (40/106) had a solid tumor diagnosis. Further breakdown of cancer type and cancer status is summarized in **Table 1**. The majority of patients, 75% (80/106), were being actively treated at the time of receiving their booster vaccine.

Serology results

Thirty three percent of the patients (35/106) were seronegative after 2 doses. At 4 weeks following the receipt of the booster vaccine, 57% (20/35) of these patients seroconverted and had a detectable antibody response as demonstrated by anti-S antibody testing, meeting the primary endpoint of our study. The median titer at baseline for the entire cohort was 212.1 AU/mL (IQR 50-2873 AU/mL) and the median titer at 4 weeks for the entire cohort was 9997 AU/mL (IQR 880.7-47063 AU/mL) (**Fig 1A**). The median rise in anti-S titer for patients with hematologic malignancies was 2167 AU/mL (IQR 0-10131 AU/mL) versus 31010 AU/mL (IQR 9531-44464 AU/mL) in patients with solid malignancies (p<0.001). Within the hematologic malignancies, patients with lymphoid cancers had a lower rise in median anti-S titers (1169 AU/mL, IQR 0-8661 AU/mL) compared to those with myeloid malignancies; median anti-S titer 9424 AU/mL (IQR 4381-20444 AU/mL) (p<0.001) (**Fig 1B**).

We further investigated the association of specific anti-cancer therapies with th booster effect. Patients on BTKi therapy (n=12) had a median rise in anti-S antibody of 0 AU/mL (IQR 0-3393 AU/mL) compared to a median rise of 9355 AU/mL (IQR 877.3-34410 AU/mL) in anti-S antibody for patients not on BTKi (p<0.05) (**Fig 1C**). Patients on anti-CD20 antibody therapy (n=25) also had a median rise in anti-S antibody level of 0 AU/mL (IQR 0-910.5 AU/mL) compared to a median rise of 12735 AU/mL (IQR 2842-38863 AU/mL) in patients that did not receive anti-CD20 antibody therapy (p<0.05). (**Fig 1D**). Nine patients had a history of SARS-CoV-2 infection and in this cohort the rise in anti-S titers was higher (median 19350 AU/mL, IQR 9286-32151 AU/mL), compared to those who did not have prior SARS-CoV-2 infection with a median anti-S titer rise, 6706 AU/mL (IQR 444.1-33831 AU/mL). (**Fig 1E**). We also observed that the rise in anti-S titer at 4 weeks was higher for patients who received a mRNA-1273 booster compared to BNT162b2 booster; median 31451 AU/mL vs 5534 AU/mL respectively (**Fig 1F**). This observation was not however, statistically significant. These results are also summarized in

Table 2.

T cell immune responses

278

288

- We also studied T-cell immune responses through a SARS-CoV-2 interferon gamma release
- assay. At baseline, 88 patients had evaluable T-cell results and a positive T cell response
- against SARS-CoV-2 was seen in 74% (65/88) patients. Of these, 21 patients were
- seronegative for anti-S antibody at baseline. At 4 weeks, 89 patients had evaluable T-cell
- results and a positive result was seen in 85% (76/89) percent patients. Of the 15 patients with
- negative anti-S antibody at 4 weeks, 11 had a positive T-cell response. Fourteen patients who
- had a negative T-cell assay response at baseline had a positive T-cell response at 4 weeks.
- Anti-S titer showed a positive correlation with T-cell response at baseline and at 4 weeks for this
- cohort (p<0.001) (Fig 1G). These results are summarized in Table 2.

Neutralization assays

- Neutralization assay against wild type virus
- We tested neutralization pre- and post-3rd dose in this cohort using the GenScript surrogate
- virus neutralization assay. At baseline, biobanked samples from 103 patients were tested for
- 292 neutralizing antibodies. Of these, 35 patients were seronegative at baseline and 68 patients
- were seropositive. Neutralizing antibodies were detected in 47 of 68 (69%) patients who were
- seropositive at baseline. The correlation between seropositivity and presence of neutralizing
- antibodies was statistically significant (p<0.001, Fisher's exact test).
- 296 At 4 weeks post 3rd dose, samples from 100 patients were available for testing. Eighty five of
- these patients were seropositive at 4 weeks and 15 were seronegative. Neutralizing antibodies
- were detected in 77 of 85 (91%) seropositive patients at 4 weeks. The correlation between
- seropositivity and presence of neutralizing antibodies was also statistically significant at 4 weeks
- 300 (p<0.001, Fisher's exact test).
- We also analyzed the correlation of anti-S titers at baseline and 4 weeks to the percentage of
- 302 virus neutralization, with 30% or more neutralization being consistent with positive result for
- detection of neutralizing antibodies. We observed that at baseline and 4 weeks, anti-S titers
- 304 correlated with percentage of viral neutralization with higher titers correlating with higher
- percentage of viral neutralization (Figure 1H < 0.001 by Spearman rank correlation). These
- results are summarized in **Table 2**.
- 307 Neutralization against Omicron BA.1
- Thirty-five patients were found be seronegative after the 3rd dose. Due to the emergence of the
- 309 Omicron BA.1 wave, we further assessed neutralization activity for the seronegative cohort
- 310 (N=35) against wild type (WT) SARS-CoV-2 and BA 1.1.529 (Omicron BA.1). At 4 weeks
- neutralization was noted in 46% patients (16/35) for the WT virus while only 17% of patients had
- detectable neutralization activity (6/35) for the Omicron variant. These results are summarized
- 313 in **Table 2**.

314 Six-month follow-up post 3rd dose of vaccine

- Forty seven patients (44%) out of 106 completed 4-6 months follow-up for the third dose study.
- All these patients were seropositive 4 weeks after the 3rd dose and strikingly, we observed that
- all patients maintained a positive anti-S antibody at 4-6 months follow-up. Eleven of these 47
- 318 patients had solid malignancies and 36 had hematologic malignancies. Six patients had

received anti-Covid monoclonal antibody (moAb) therapy as per standard of care (4 tixagevimab-cilgavimab or Evusheld, 1 casirivimab/imdevimab or regen-co-v, and 1 sotrovimab between the 4-week and 4-6 months follow-up. A striking increase in titers in this small cohort of patients was noted to a median titer of 17481.2 AU/mL. Four patients had breakthrough SARS-CoV-2 infections and 9 patients had received a 4th dose of COVID-19 vaccine outside of the context of the study prior to the time of 4-6 month follow-up. The median decline in titer for 41 patients who did not receive anti-SARS-CoV-2 moAb treatment in the interim to confound results was -922.2 AU/mL. When compared to the antibody levels 4 weeks after booster vaccination, the median percentage decline in titers was 56.4%. However, despite the noted decline not a single patient in this cohort seroreverted (Fig 11), especially when compared to decline post 2 vaccines. In our initial report of seroconversion post-3rd booster, we reported waning of immunity in 99 patients post 2 vaccines. The median decline in the 99 patient cohort was 72.1% with 2 patients losing detectable antibody response [17]

Efficacy of 4th dose vaccine for patients that were seronegative or low seropositive after

3rd dose 334

319

320

321 322

323

324

325

326 327

328

329

330 331

332

333

335

336

337

338

339

340

341 342

343

344

347

351

354

355

357

358

Baseline characteristics

- Eighteen patients were enrolled into the 4th dose study. Median age for this cohort was 69.5 years (IQR 65.5-73.8). Thirty nine percent (7/18) were seronegative at baseline and 61% patients (11/18) were sero-low (anti-S ab <1000 AU/mL). All patients had hematologic malignancies in this cohort and the breakdown of diagnoses is provided in Table 3. Eighty three percent of the patients (15/18) received BNT162b2 4th booster shots and 17% (3/18) patients received Ad26.CoV2.S as their 4th booster vaccine. In addition, we also measured baseline complete blood counts (CBC), lymphocyte subsets, immunoglobulin G, A and M (quantitative lg) levels at baseline and 4 weeks. (Table 4).
 - Anti-spike IgG responses after the 4th dose

A patient was classified as a responder if they 1) had positive anti-S antibody at 4 weeks if 345 seronegative at baseline or 2) if they achieved a titer of >1000 AU/mL at 4 weeks if they were 346 sero-low at baseline. As such, we observed a 67% response rate (12/18) in patients for the 4th dose cohort. Two of 7 seronegative patients seroconverted to positive anti-S antibody at 4 348 weeks with a seroconversion rate of 29% in this cohort. All low seronegative patients (11/11) 349 responded with an IgG level > 1000 after the 4th dose (Fig 2A). For the whole cohort, the 350 median anti-S antibody at baseline was 131.1 AU/mL (<50-432.9 AU/mL) and at 4 weeks was 352 1700 AU/mL (IQR 64.3-18627 AU/mL). We further investigated association of baseline 353 laboratory values, such as CBC, lymphocyte subsets and quantitative Iq levels and observed that patients in the responder group had higher baseline IgM (60.5 mg/dl) compared with the non-responder group (median 17 mg/dl, p<0.001) (Fig 2B). Additionally, we also observed that 356 the median CD19+ cell count was significantly lower in the non-responder group versus the responder group (1 vs 113, p=0.04). These results are summarized in Table 5.

T Cell activity against SARS-CoV-2 after the 4th dose

T-cell activity was assessed at baseline and at 4 weeks using the SARS-CoV-2 interferon 359 gamma release assay. At baseline, 14 patients had evaluable T-cell responses and a positive 360

- response was noted in 79% patients (11/14). Of these, 3 patients had negative anti-S antibody
- at baseline. At 4 weeks after the 4th dose, a positive T-cell response was seen in 17/18 (94%)
- patients. These results are summarized in **Table 5**.

Neutralization activity against SARS-CoV-2 after 4th dose

- We also assessed neutralization activity at baseline and at 4 weeks against WT and Omicron (B
- 1.1.529, BA.1). The results are summarized in **Table 5**. Overall, neutralization activity was seen
- in 67% patient samples at baseline and in 72% patient samples at 4 weeks. Strikingly,
- neutralization activity against Omicron was absent in all patient samples at baseline, however
- became detectable in 33% (6/18) patients at 4 weeks after the 4th dose. The titer of anti-S
- antibody correlated with neutralization activity at baseline and at 4 weeks against the WT virus
- 371 (p<0.001) (Fig 2C). We also observed correlation between the titer of anti-S antibody with
- neutralization activity at 4 weeks for the Omicron variant (**Fig 2D**).

Exploratory analysis for immunoglobulin levels

- The observation for baseline IgM correlating with response to the 4th dose of the COVID-19
- vaccine led us to perform an exploratory analysis to assess if IgG and IgA levels would also
- 376 correlate with the response. Given that our 4th dose cohort was small, we performed this
- 377 exploratory analysis by combining the baseline immunoglobulin levels for the baseline
- 378 seronegative cohort for the 3rd dose study (n=35) and baseline immunoglobulin levels for the 4th
- dose study (n=18). In this exploratory analysis, we observed that the median levels for all
- immunoglobulin subtypes were lower in patients who either did not seroconvert after the 3rd
- dose or did not respond to the 4th dose (IgA 49 mg/dL vs 116.5 mg/dL, IgM 16.6 mg/dL vs 48.3
- 382 mg/dL, lgG 488 mg/dL vs 759.5 mg/dL with p values of 0.05, 0.002 and 0.006 respectively
- 383 (Kruskal Wallis test).

Discussion

364

373

384

- 385 Since the authorization of 3rd doses for patients with a weakened immune system, several
- studies have shown enhanced immunogenicity for a third dose of COVID-19 vaccine in patients
- with cancer. [17, 24, 25] In particular, patients with lymphoid malignancies have been
- consistently shown to have reduced seroconversion after 2 doses of the COVID-19 vaccines[26-
- 389 29]. Studies looking at immunogenicity of a 3rd dose of COVID-19 vaccines have reported that a
- subset of these patients can be induced to have an immune response with the 3rd dose of the
- 391 COVID-19 vaccines.[17, 30]
- 392 Correlation between anti-S antibody titers and neutralization activity in patients with cancer has
- been demonstrated [31]. However, the emergence of the Omicron (B.1.1.529) variant which was
- discovered in November 2021 and then spread quickly globally, the situation changed. Omicron,
- with its extensive mutations in neutralizing epitopes, is able to at least partially evade in vitro
- neutralizing antibodies induced by 3rd doses in patients with cancer[31, 32]. The potential utility
- and timing of a 4th COVID-19 vaccine dose has been brought up especially for those who are at
- risk for poor seroconversion after 3rd doses[33], with the Centers for Disease Control (CDC)
- recommending 2 additional boosters following a 3-vaccine primary series[34]. These variants in
- part overcome vaccine-induced immunity and are resistant to many of the available monoclonal
- 401 antibody products[31, 32, 35].

Our results demonstrate that a 3rd dose of COVID-19 vaccine boosts detectable anti-SARS-CoV-2 immunity in the majority of cancer patients and can seroconvert a subset of them not responding to prior vaccine doses. The 3rd COVID-19 vaccine also results in boosting of T-cell responses and leads to a rise in neutralizing antibodies. Patients who have received anti-CD20 antibody therapy or BTK inhibitors remain at risk for lower seroconversion whereas those who have been infected with COVID-19 in the past, have a very strong immune response likely due to immunologic memory. Our results show that the higher the titer of the anti-S antibody, the higher likelihood of neutralization in a surrogate neutralization assay adding to the evidence that this may be a good strategy to prevent symptomatic SARS-CoV-2 infection as well as an appropriate surrogate marker to guide research and clinical management [36]. Our study also provides the reassuring finding that the large majority of patients with cancer retain detectable humoral immunity at 6 months post 3rd dose of COVID-19 vaccination.

Reports of efficacy of 4th COVID-19 vaccine doses are emerging. A study from Israel demonstrated enhanced Omicron neutralization after a 4th dose of COVID-19 mRNA vaccine in healthy health-care workers[37]. However a study of 25 patients with solid organ transplant recipients showed that the 4th dose was not effective in inducing Omicron neutralization[38]. Such a study has not been published yet for patients with cancer, making this an unmet need. We designed a prospective cohort study of a 4th dose of the COVID-19 vaccine in patients with cancer precisely to address this question. Our results suggest that in cohorts of highly immune suppressed patients, baseline assessment of immunity based on prior treatment history and immunological markers such as IgM levels and CD19+ cell levels may help predict the response to COVID-19 booster vaccinations and support administration of additional vaccine doses even in highly immune suppressed individuals. Notably, serum IgM levels were previously shown to correlate with mRNA vaccine responses of solid organ transplant recipients[39]. In addition, further testing to assess serological and cellular markers of the response may be helpful to identify the patients at highest risk to prioritize these patients for preventive/prophylactic strategies as well as enrichment markers for further experimental studies. Finally, the 4th vaccine dose results in a significant increase in anti-spike antibodies in low seropositive patients and seroconversion in a proportion of seronegative immunosuppressed patients with cancer. Similar to previous reports, the booster doses do lead to enhanced neutralization activity against the WT virus, but not the Omicron (BA.1) variant. Future efforts are needed to evaluate variantspecific vaccines as well as additional protective measures, such as passive immunization strategies, especially for this immunosuppressed patient population that may not benefit as much as healthy controls from booster doses of existing vaccines.

References

403

404

405

406

407

408

409

410 411

412

413

414 415

416

417

418 419

420

421 422

423

424 425

426

427

428

429

430

431 432

433 434

435

436

- 440 1. Kuderer, N.M., et al., Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, 2020. **395**(10241): p. 1907-1918.
- Lee, L.Y.W., et al., COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol, 2020. **21**(10): p. 1309-1316.
- Mehta, V., et al., Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov, 2020. **10**(7): p. 935-941.

- 447 4. Khoury, E., et al., Differences in Outcomes and Factors Associated With Mortality Among
 448 Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A
 449 Systematic Review and Meta-analysis. JAMA Netw Open, 2022. **5**(5): p. e2210880.
- Tang, L.V. and Y. Hu, *Poor clinical outcomes for patients with cancer during the COVID-19 pandemic.* Lancet Oncol, 2020. **21**(7): p. 862-864.
- 452 6. Lee, M., et al., Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. Cancer Cell, 2022. **40**(4): p. 343-345.
- Pinato, D.J., et al., Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncol, 2022.
- 457 8. Bestvina, C.M., et al., COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related 458 Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis. JTO Clin Res Rep, 459 2022: p. 100335.
- Grivas, P., et al., Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol, 2021. 32(6): p. 787-800.
- 463 10. Sadoff, J., et al., *Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.* N Engl J Med, 2021. **384**(23): p. 2187-2201.
- 465 11. Polack, F.P., et al., *Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.* N Engl J Med, 2020. **383**(27): p. 2603-2615.
- Thakkar, A., et al., Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell, 2021. **39**(8): p. 1081-1090.e2.
- 469 13. Addeo, A., et al., *Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.* Cancer Cell, 2021. **39**(8): p. 1091-1098.e2.
- 471 14. Schönlein, M., et al., Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study. Cancer Cell, 2022.
- 473 15. Guven, D.C., et al., *Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.* Oncologist, 2022. **27**(4): p. e357-e361.
- Dahiya, S., et al., Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy. Blood Adv, 2022. **6**(2): p. 686-689.
- 477 17. Shapiro, L.C., et al., *Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer*. Cancer Cell, 2022. **40**(1): p. 3-5.
- 479 18. Pillay, T.S., Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol, 2020. **73**(7): p. 366-369.
- 481 19. Yang, J., et al., *Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.*482 Nat Commun, 2020. **11**(1): p. 4541.
- 483 20. Bradley, B.T., et al., Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2
 484 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of
 485 Sterilizing Immunity. J Clin Microbiol, 2021. **59**(9): p. e0098921.
- 486 21. Carreño, J.M., et al., *Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.*487 Nature, 2022. **602**(7898): p. 682-688.
- 488 22. Amanat, F., et al., *An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug*489 *Screening.* Curr Protoc Microbiol, 2020. **58**(1): p. e108.
- 23. Zhao, Y.D., et al., *Testing homogeneity of stratum effects in stratified paired binary data*. J Biopharm Stat, 2014. **24**(3): p. 600-7.
- 492 24. Munro, A.P.S., et al., Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a

- blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, 2021. **398**(10318): p. 2258-2276.
- Shroff, R.T., et al., *Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.* Nat Med, 2021. **27**(11): p. 2002-2011.
- 498 26. Greenberger, L.M., et al., *Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies*. Cancer Cell, 2021. **39**(8): p. 1031-1033.
- Perry, C., et al., Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv, 2021. **5**(16): p. 3053-3061.
- Herishanu, Y., et al., Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood, 2021. **137**(23): p. 3165-3173.
- 504 29. Ghione, P., et al., *Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.* Blood, 2021. **138**(9): p. 811-814.
- 506 30. Lim, S.H., et al., *Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.* Nat Cancer, 2022. **3**(5): p. 552-564.
- Mack, P.C., et al., Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. Cancer Cell, 2022.
- 510 32. Chang, A., et al., Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA 511 Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. J Clin 512 Oncol, 2022: p. Jco2200088.
- 513 33. Ehmsen, S., et al., Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination. Cancer Cell, 2022. **40**(4): p. 338-339.
- 515 34. <COVID-19 Vaccines for People who are Moderately or Severely Immunocompromised _ 516 CDC.pdf>.
- 517 35. Zhou, H., et al., SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies. bioRxiv, 2022: p. 2022.02.15.480166.
- 519 36. Khoury, D.S., et al., *Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.* Nat Med, 2021. **27**(7): p. 1205-1211.
- 521 37. Regev-Yochay, G., et al., *Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.* N Engl J Med, 2022. **386**(14): p. 1377-1380.
- 523 38. Karaba, A.H., et al., A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the 524 Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. 525 Transplantation, 2022.
- 526 39. Azzi, Y., et al., *Risk factors associated with poor response to COVID-19 vaccination in kidney transplant recipients.* Kidney Int, 2021. **100**(5): p. 1127-1128.

Table 1: Baseline characteristics for 3rd dose cohort.

Baseline characteristics	n=106
Age (median, IQR)	68 (63.25-76.5)
Sex	
Male	48(45%)
Female	58(55%)
Race	
Caucasian	36(34%)
African-American	33(31%)
Hispanic	27(25%)

Asian	9(8%)
Other	1(1%)
Previous vaccine given	
BNT162b2	72(68%)
mRNA-1273	28(26%)
Ad26.CoV2.S	6(6%)
Type of booster vaccine	
BNT162b2	78(74%)
mRNA-1273	28(26%)
Malignancy category	
Hematologic malignancy	66(62%)
Solid Malignancy	40(38%)
Lymphoid/Myeloid/Solid	
Lymphoid	55(52%)
Myeloid	11(10%)
Solid	40(38%)
Cancer status	
Active	69(65%)
Progressive	3(3%)
Recurrent	3(3%)
Relapse	7(7%)
Remission	24(23%)
On treatment at the time of booster	
Yes	80(75%)
No	26(25%)

Table 2. Results for 3rd dose of vaccine.				
Spike antibody results		n=106		
	4-week negative	4-week positive	Seroconversio n rate	p value
Baseline negative	15	20	57%	<0.001
Baseline positive	0	71		
Total	15	91		
Rise in spike antibody titers overall (AU/mL)	Median	IQR		
Titer at baseline	212.1	50-2873		
Titer at 4 weeks	9997	880.7- 47063		
Rise in spike antibody titers (AU/mL)	Median	IQR		

Hematologic malignancy	2167	0-10131	<0.001
Solid malignancy	31010	9531-44464	
Rise in spike antibody titers by solid/lymphoid/myeloid (AU/mL)			
Lymphoid cancers	1169	0-8661	<0.001
Myeloid cancers	9424	4381-20444	
Solid cancers	31010	9531-44464	
Association with certain cancer- directed therapies			
Bruton's tyrosine kinase inhibitors			
Change in spike antibody titers (AU/mL)	Median	IQR	
Patients on BTKi (n=12)	0	0-3393	<0.001
Patients not on BTKi	9355	877.3- 34410	
Anti-CD20 antibody treatment			
Change in spike antibody titers (AU/mL)	Median	IQR	
Patients on CD20 (n=25)	0	0-910.5	0.0133*
Patients not on CD20	12735	2842-38863	
Anti-CD20 antibody treatment within 6 months	Median	IQR	
Yes	0	0-0	0.0548 2
No	587	0-4314	
Change in spike antibody titer by prior COVID infection	Median	IQR	
Yes (n=9)	19350	9286-32151	0.3051
No (n=96)	6706	444.1- 33831	
Change in spike antibody titer by type of booster given	Median	IQR	
BNT162b2	5534	433.8- 18074	0.0901 4
mRNA-1273	31451	515.5- 45057	
T-cell activity			
Baseline	n=88	%	
Positive	65	74%	
Negative	23	26%	
4-week	n=89		
Positive	76	85%	
Negative	13	15%	

Baseline Neutralization activity assay (all evaluable patients, WT virus)				
		Anti-S		
	Anti-S antibody negative	antibody positive	Total	p value
Neutralizing antibodies detected	0	47	47	<0.001
Neutralizing antibodies not detected	35	21	56	
Total	35	68	103	
Four-week Neutralization activity assay (all evaluable patients, WT virus)				
	Anti-S antibody negative	Anti-S antibody positive	Total	p value
Neutralizing antibodies detected	0	77	77	<0.001
Neutralizing antibodies not detected	15	8	23	
Total	15	85	100	
Four week Neutralization assay (seronegative cohort 4 weeks)	n=35			
Wild type				
Negative	19	54%		
Positive	16	46%		
Omicron				
Negative	29	83%		
Positive	6	17%		

Table 3: Baseline characteristics of the 4th dose cohort.		
	N (%)	
Baseline seronegative	7 (39%)	
Baseline low positive (Spike ab <1000		
AU/mL)	11 (61%)	
Cancer diagnosis		
CLL	7 (39%)	
Waldenstrom's Macroglobulinemia	3 (17%)	
DLBCL	2 (11%)	
Multiple Myeloma	2 (11%)	
Mantle Cell Lymphoma	1 (6%)	
Marginal Zone lymphoma	1 (6%)	
Hodgkins lymphoma	1 (6%)	
MDS	1 (6%)	

Fourth dose vaccine type	
BNT162b2	15 (83%)
Ad26.CoV2.S	3 (17%)

Table 4: Correlation of 4th dose vaccine response with baseline characteristics.			
	Non-responder (n=6)	Responder (n=12)	p value
Age	79.5	67.5	0.01293 *
Baseline WBC	4.95	5.15	0.45
Baseline ANC	2.6	3.5	0.26
Baseline ALC	1.2	1.3	0.57
Baseline AMC	0.5	0.65	0.73
Baseline Absolute CD3	773	835.5	0.57
Baseline Absolute CD4	406.5	407.5	0.71
Baseline Absolute CD8	310	247	0.40
Baseline Absolute CD19	1	113.5	0.04874 *
Baseline Absolute CD16/56	243.5	200	0.57
Baseline IgG	777	757	0.51
Baseline IgA	90.5	118	0.57
Baseline IgM	17	60.5	0.001442 * *
4 week WBC	5.1	5.8	0.40
4 week ANC	2.7	3.45	0.57
4 week ALC	1.1	1.4	0.60
4 week AMC	0.55	0.65	0.60
4 week absolute CD3	754	983	0.40
4 week absolute CD4	461.5	369.5	0.93
4 week absolute CD8	297.5	269	0.40
4 week absolute CD19	2.5	105	0.07
4 week absolute CD16/56	232.5	219	0.93
4 week IgG*	741.5	832	0.62
4 week IgA*	86	112	0.69
4 week IgM*	15	62	0.003561 * *
*n=11 for responder group			

Table 5: Results for 4th dose study.			
Overall response	18		
Responder	12	67%	
Non-responder	6	33%	
Median age		IQR	
			0.01293
Responder	67.5	63.75- 70.75	*
Non-responder	79.5	72.75- 81.75	
Median baseline IgM			

			0.001442
Responder	60.5		* *
Non-responder	17		
Median spike antibody at			
baseline (AU/mL)	131.1	<50-432.9	
Median spike antibody at 4			
weeks (AU/mL)	1700	64.3-18627	
T-cell activity at baseline	n=14		
Positive	11	79%	
Negative	3	21%	
T cell activity at 4 weeks	n=18		
Positive	17	94%	
Negative	1	6%	
Baseline			
Neutralization assay baseline	Negative	Positive	
WT	6(33%)	12(67%)	
Omicron	18(100%)	0(0%)	
Neutralization assay 4 week	Negative	Positive	
WT	5(28%)	13(72%)	
Omicron	12(67%)	6(33%)	

Table legend:

533

534

540

- Table 1: Baseline characteristics of 3rd dose cohort
- Table 2: Summary of results for 3rd dose cohort
- Table 3: Baseline characteristics for 4th dose cohort
- Table 4: Correlation of baseline characteristics with outcome for 4th dose cohort
- Table 5: Summary of results for 4th dose cohort

Figure legend

- Figure 1: Immunogenicity of 3rd dose of COVID-19 vaccine in seronegative cancer patients
- Figure 1A: Figure showing change in anti-S antibody titer at 4 weeks for entire cohort
- Figure 1B: Figure showing change in anti-S antibody titer at 4 weeks split by cancer type (solid
- 544 cancer, lymphoid cancer and myeloid cancer)
- Figure 1C: Figure showing effect of Bruton's tyrosine kinase inhibitor (BTKi) therapy on anti-S
- antibody titer at baseline and 4 weeks of 3rd dose
- Figure 1D: Figure showing effect of anti-CD20 antibody therapy on anti-S antibody titer at
- 548 baseline and 4 weeks of 3rd dose
- Figure 1E: Figure showing effect of prior COVID-19 infection on anti-S antibody titer at baseline
- and 4 weeks of 3rd dose

- Figure 1F: Figure showing effect of booster type (BNT162b2 vs mRNA 1273) on anti-S antibody
- titer at baseline and 4 weeks of 3rd dose.
- Figure 1G: Line diagram showing correlation between anti-Spike IgG titer and baseline T-cell
- activity at baseline and 4 weeks
- Figure 1H: Line diagram showing correlation between anti-S titer and signal inhibition for
- neutralization against WT virus at baseline and 4 weeks.
- Figure 1I: Anti-Spike IgG titres at baseline, 4 weeks and 6 months after 3rd dose of COVID-19
- vaccine in cancer patients. Line shows means with error bars (S.D.).
- Figure 2: Immunogenicity of the 4th dose of COVID-19 vaccine in cancer patients with
- seronegativity after 3 doses

- Figure 2A: Anti-spike IgG levels after the 4th dose of COVID-19 vaccine for the entire cohort
- Figure 2B: Correlation of baseline IgM levels with response to 4th dose of vaccine
- Figure 2C: Line diagram showing correlation between anti-S titer and neutralization activity for
- 564 WT virus at baseline and 4 weeks
- Figure 2D: Line diagram showing correlation between titer and neutralization activity for
- 566 Omicron strain at baseline and 4 weeks
- Acknowledgements: This study was supported with funding from the National Cancer Institute
- 569 Grant 3P30CA013330-49S3 and NCORP Grant 2UG1CA189859-06. The authors also
- acknowledge support from the Jane and Myles Dempsey Family. The funders had no role in
- 571 study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Work in the Krammer laboratory was partially funded by the Centers of Excellence for Influenza
- 573 Research and Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of
- 574 Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014), by
- the Collaborative Influenza Vaccine Innovation Centers (CIVICs contract # 75N93019C00051)
- and by institutional funds. Finally, this effort was also supported by the Serological Sciences
- Network (SeroNet) in part with Federal funds from the National Cancer Institute, National
- Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003.
- 579 The content of this publication does not necessarily reflect the views or policies of the
- Department of Health and Human Services, nor does mention of trade names, commercial
- products or organizations imply endorsement by the U.S. Government.
- Author contributions: Conception and design: AT, LCS, LAP, BH, AV. Patient referral
- recruitment and follow-up: AT, LCS, BD, IM. Data curation: AT, LCS, Laboratory investigations:

- JMCQ, SS, VT, SC, TDB, JR, RO, MS. Logistical support : ML, RQ. Administrative support: EC, BW, FK, Data analysis: KP, All authors contributed to the writing of the manuscript.
- Conflict of interest statement: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines
- which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to
- market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer
- 591 (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex.
- The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.




Figure 1: Immunogenicity of 3rd dose of COVID-19 vaccine in seronegative cancer patients

Figure 1A: Figure showing change in anti-S antibody titer at 4 weeks for entire cohort

Figure 1B: Figure showing change in anti-S antibody titer at 4 weeks split by cancer type (solid cancer, lymphoid cancer and myeloid cancer)

Figure 1C: Figure showing effect of Bruton's tyrosine kinase inhibitor (BTKi) therapy on anti-S antibody titer at baseline and 4 weeks of 3rd dose

Figure 1D: Figure showing effect of anti-CD20 antibody therapy on anti-S antibody titer at baseline and 4 weeks of 3rd dose

Figure 1E: Figure showing effect of prior COVID-19 infection on anti-S antibody titer at baseline and 4 weeks of 3rd dose

Figure 1F: Figure showing effect of booster type (BNT162b2 vs mRNA 1273) on anti-S antibody titer at baseline and 4 weeks of 3rd dose.

Figure 1G: Line diagram showing correlation between anti-Spike IgG titer and baseline T-cell activity at baseline and 4 weeks

Figure 1H: Line diagram showing correlation between anti-S titer and signal inhibition for neutralization against WT virus at baseline and 4 weeks.

Figure 1I: Anti-Spike IgG titres at baseline, 4 weeks and 6 months after 3rd dose of COVID-19 vaccine in cancer patients. Line shows means with error bars (S.D.).




Figure 2: Immunogenicity of the 4th dose of COVID-19 vaccine in cancer patients with seronegativity after 3 doses

- Figure 2A: Anti-spike IgG levels after the 4th dose of COVID-19 vaccine for the entire cohort
- Figure 2B: Correlation of baseline IgM levels with response to 4th dose of vaccine
- Figure 2C: Line diagram showing correlation between anti-S titer and neutralization activity for WT virus at baseline and 4 weeks

Figure 2D: Line diagram showing correlation between titer and neutralization activity for Omicron strain at baseline and 4 weeks